0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Intravenous Immunoglobulin Market by End User, Product Type, Patient Type, Distribution Channel, Indication - Global Forecast to 2030- Product Image
Intravenous Immunoglobulin Market by End User, Product Type, Patient Type, Distribution Channel, Indication - Global Forecast to 2030- Product Image
Sale

Intravenous Immunoglobulin Market by End User, Product Type, Patient Type, Distribution Channel, Indication - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889544
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

As demand for advanced plasma-derived therapies intensifies, the intravenous immunoglobulin market presents critical opportunities for healthcare leaders aiming to address evolving patient care challenges, optimize supply strategies, and navigate an increasingly complex regulatory environment.

Market Snapshot: Intravenous Immunoglobulin Market Overview

The intravenous immunoglobulin market grew from USD 1.33 billion in 2024 to USD 1.43 billion in 2025. It is projected to achieve a CAGR of 6.94%, reaching USD 2.00 billion by 2030. This sector’s expansion is driven by rising global incidences of autoimmune and neurological disorders, expanded regulatory approvals, and advances in manufacturing and purification technologies. Continual efforts in supply chain optimization and improvements in patient-centric care underpin broader and more reliable access, positioning intravenous immunoglobulin as a cornerstone in immune modulation and replacement therapies.

Scope & Segmentation

  • End Users: Home care, private and public hospitals, and specialty clinics focusing on hematology, immunology, and neurology.
  • Product Types: High purity immunoglobulin formulations and normal immunoglobulin offered in both liquid and lyophilized (freeze-dried) formats.
  • Patient Types: Adults, geriatric individuals, and pediatric patients, each with specific dosing and care requirements.
  • Distribution Channels: Direct sales, hospital pharmacies, retail pharmacies, and wholesale distributors supporting various care settings.
  • Clinical Indications: Autoimmune diseases, major hematological conditions, primary and secondary immunodeficiency disorders, and neurological disorders responsive to immunoglobulin intervention.
  • Regional Coverage: Americas (including major US states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with diverse representation across Western Europe, Middle Eastern economies, and African nations), and Asia-Pacific (covering both developed and emerging markets such as China, India, and Japan).
  • Key Companies Analyzed: CSL Limited, Grifols S.A., Takeda Pharmaceutical Company Limited, Octapharma AG, Baxter International Inc., Biotest AG, Bio Products Laboratory Limited, Kedrion S.p.A., LFB S.A., Shanghai RAAS Blood Products Co., Ltd.

Key Takeaways: Strategic Insights for Market Decision-Makers

  • Advanced fractionation and continuous manufacturing reduce historical supply challenges, supporting a more resilient and efficient pipeline for finished products.
  • Regulatory harmonization is lowering barriers for innovative therapies and biosimilar competition, enhancing accessibility and market diversity in major markets.
  • The application of pharmacokinetic modeling and biomarker-based dosing is shaping more targeted, cost-efficient treatment regimens, particularly in specialized clinical settings.
  • Digital health solutions, such as telemedicine-assisted infusion monitoring and electronic health record analytics, are improving patient adherence and enabling more precise treatment adjustments.
  • Emerging clinical applications extend the therapy’s reach beyond conventional indications, including novel neurological and pediatric uses under expanded access and compassionate use protocols.
  • Strategic alliances—ranging from specialty clinic partnerships to local plasma collection initiatives—are increasingly critical to sustaining market share and driving innovation.

Tariff Impact: Assessing 2025 US Policy Shifts

The 2025 US tiered tariff framework is impacting international suppliers and domestic distributors by raising import costs for plasma-derived products. Healthcare providers face renewed budgeting pressures, prompting a shift toward supply chain localization and the use of alternative formulations. Manufacturers are responding with greater focus on local plasma collection, contract manufacturing investments, and flexible pricing strategies. Stakeholders with established domestic infrastructure are positioned to better absorb and navigate tariff-induced market shifts.

Methodology & Data Sources

This report leverages a hybrid research approach, integrating insights from expert interviews with comprehensive secondary data from regulatory agencies, clinical publications, and industry financial reports. Rigorous data triangulation validates segmentation performance, regional trends, and vendor strategies, ensuring that all findings reflect industry best practices and high standards of data integrity.

Why This Report Matters

  • Enables leaders to benchmark strategies against pivotal technological, regulatory, and competitive trends shaping the intravenous immunoglobulin sector.
  • Provides actionable intelligence for investment prioritization, market entry, and product portfolio expansion in a rapidly changing therapeutic landscape.
  • Supports informed decision-making with a granular, evidence-based analysis of region- and segment-specific opportunities.

Conclusion

With technology, supply chains, and patient-centric care models evolving rapidly, the intravenous immunoglobulin market offers substantial opportunities for forward-thinking organizations. Strategic integration of advanced manufacturing, digital health, and data-driven approaches will be key to sustaining growth and optimizing patient access in this critical therapeutic field.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Intravenous Immunoglobulin Market, by End User
8.1. Introduction
8.2. Home Care
8.3. Hospital
8.3.1. Private Hospital
8.3.2. Public Hospital
8.4. Specialty Clinic
8.4.1. Hematology Clinic
8.4.2. Immunology Clinic
8.4.3. Neurology Clinic
9. Intravenous Immunoglobulin Market, by Product Type
9.1. Introduction
9.2. High Purity Immunoglobulin
9.3. Normal Immunoglobulin
9.3.1. Liquid
9.3.2. Lyophilized
10. Intravenous Immunoglobulin Market, by Patient Type
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Intravenous Immunoglobulin Market, by Distribution Channel
11.1. Introduction
11.2. Direct Sales
11.3. Hospital Pharmacy
11.4. Retail Pharmacy
11.5. Wholesale Distributor
12. Intravenous Immunoglobulin Market, by Indication
12.1. Introduction
12.2. Autoimmune Diseases
12.2.1. Guillain-Barré Syndrome
12.2.2. Immune Thrombocytopenic Purpura
12.2.3. Kawasaki Disease
12.3. Hematological Conditions
12.3.1. Hemolytic Disease of the Newborn
12.4. Immunodeficiency Disorders
12.4.1. Primary Immunodeficiency
12.4.2. Secondary Immunodeficiency
12.5. Neurological Disorders
12.5.1. Chronic Inflammatory Demyelinating Polyneuropathy
12.5.2. Multifocal Motor Neuropathy
13. Americas Intravenous Immunoglobulin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Intravenous Immunoglobulin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Intravenous Immunoglobulin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. CSL Limited
16.3.2. Grifols, S.A.
16.3.3. Takeda Pharmaceutical Company Limited
16.3.4. Octapharma AG
16.3.5. Baxter International Inc.
16.3.6. Biotest AG
16.3.7. Bio Products Laboratory Limited
16.3.8. Kedrion S.p.A.
16.3.9. LFB S.A.
16.3.10. Shanghai RAAS Blood Products Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET MULTI-CURRENCY
FIGURE 2. INTRAVENOUS IMMUNOGLOBULIN MARKET MULTI-LANGUAGE
FIGURE 3. INTRAVENOUS IMMUNOGLOBULIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRÉ SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 75. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 77. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 78. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 79. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 80. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 84. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 85. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 86. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 87. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 89. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 90. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 91. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 92. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 96. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 148. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 150. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 151. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 152. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 153. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 157. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 158. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 159. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 160. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 162. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 163. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 165. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 169. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 170. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 171. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 184. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 186. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 187. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 188. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 189. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 193. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 194. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 195. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 196. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 198. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 199. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 200. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 201. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 205. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 206. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 207. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 232. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 244. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 246. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 247. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 249. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 250. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 253. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 254. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 255. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 268. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 270. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 271. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 272. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 273. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 277. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 278. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 279. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 280. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 282. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 283. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 285. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 286. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 288. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 289. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 290. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 291. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 304. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Intravenous Immunoglobulin market report include:
  • CSL Limited
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Baxter International Inc.
  • Biotest AG
  • Bio Products Laboratory Limited
  • Kedrion S.p.A.
  • LFB S.A.
  • Shanghai RAAS Blood Products Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.43 Billion
Forecasted Market Value ( USD ) by 2030 $ 2 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 153 Pages
  • Global
From
EUR$5,950USDGBP
Intravenous Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033 - Product Image

Intravenous Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033

  • Report
  • 175 Pages
  • Global
From
EUR$4,500USDGBP
Intravenous Immunoglobulin (IVIG) Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application - Product Image

Intravenous Immunoglobulin (IVIG) Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application

  • Report
  • 94 Pages
  • Global
From
EUR$4,238USDGBP
Intravenous Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Intravenous Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
EUR$3,250USDGBP
EUR$4,850USDGBP
Immunoglobulin Product Market by Source, Product Type, Route of Administration, Distribution Channel, Application - Global Forecast to 2030 - Product Image

Immunoglobulin Product Market by Source, Product Type, Route of Administration, Distribution Channel, Application - Global Forecast to 2030

  • Report
  • 195 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP

About the Intravenous Immunoglobulin Market

The Intravenous Immunoglobulin (IVIG) market is a subset of the biotechnology industry that focuses on the production and distribution of immunoglobulin products. IVIG is a blood product derived from the pooled plasma of healthy donors, and is used to treat a variety of conditions, including autoimmune diseases, infections, and immunodeficiencies. IVIG is also used in the prevention of certain infections in immunocompromised patients. IVIG is produced by a number of companies, including CSL Behring, Grifols, Kedrion, Octapharma, and Biotest. These companies are involved in the production, distribution, and marketing of IVIG products. They also provide support services such as patient education, reimbursement assistance, and clinical trial support. Additionally, some companies are involved in the development of new IVIG products, such as recombinant immunoglobulins and monoclonal antibodies. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more